FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789873517> ?p ?o ?g. }

• W2789873517 endingPage "709" @default.
• W2789873517 startingPage "698" @default.
• W2789873517 abstract "Abstract The development of molecularly targeted agents has benefited from use of pharmacodynamic markers to identify “biologically effective doses” (BED) below MTDs, yet this knowledge remains underutilized in selecting dosage regimens and in comparing the effectiveness of targeted agents within a class. We sought to establish preclinical proof-of-concept for such pharmacodynamics-based BED regimens and effectiveness comparisons using MET kinase small-molecule inhibitors. Utilizing pharmacodynamic biomarker measurements of MET signaling (tumor pY1234/1235MET/total MET ratio) in a phase 0–like preclinical setting, we developed optimal dosage regimens for several MET kinase inhibitors and compared their antitumor efficacy in a MET-amplified gastric cancer xenograft model (SNU-5). Reductions in tumor pY1234/1235MET/total MET of 95%–99% were achievable with tolerable doses of EMD1214063/MSC2156119J (tepotinib), XL184 (cabozantinib), and XL880/GSK1363089 (foretinib), but not ARQ197 (tivantinib), which did not alter the pharmacodynamic biomarker. Duration of kinase suppression and rate of kinase recovery were specific to each agent, emphasizing the importance of developing customized dosage regimens to achieve continuous suppression of the pharmacodynamic biomarker at the required level (here, ≥90% MET kinase suppression). The customized dosage regimen of each inhibitor yielded substantial and sustained tumor regression; the equivalent effectiveness of customized dosage regimens that achieve the same level of continuous molecular target control represents preclinical proof-of-concept and illustrates the importance of proper scheduling of targeted agent BEDs. Pharmacodynamics-guided biologically effective dosage regimens (PD-BEDR) potentially offer a superior alternative to pharmacokinetic guidance (e.g., drug concentrations in surrogate tissues) for developing and making head-to-head comparisons of targeted agents. Mol Cancer Ther; 17(3); 698–709. ©2018 AACR." @default.
• W2789873517 created "2018-03-29" @default.
• W2789873517 creator A5027165899 @default.
• W2789873517 creator A5034690406 @default.
• W2789873517 creator A5036643896 @default.
• W2789873517 creator A5041200743 @default.
• W2789873517 creator A5047485406 @default.
• W2789873517 creator A5057382599 @default.
• W2789873517 creator A5072996291 @default.
• W2789873517 creator A5078802338 @default.
• W2789873517 creator A5080778766 @default.
• W2789873517 creator A5083899578 @default.
• W2789873517 creator A5089485306 @default.
• W2789873517 creator A5090468019 @default.
• W2789873517 date "2018-02-28" @default.
• W2789873517 modified "2023-09-27" @default.
• W2789873517 title "Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors" @default.
• W2789873517 cites W1516787664 @default.
• W2789873517 cites W1545792489 @default.
• W2789873517 cites W1974058738 @default.
• W2789873517 cites W1974643012 @default.
• W2789873517 cites W1985995033 @default.
• W2789873517 cites W1990371568 @default.
• W2789873517 cites W2000425014 @default.
• W2789873517 cites W2011138678 @default.
• W2789873517 cites W2012169430 @default.
• W2789873517 cites W2013678879 @default.
• W2789873517 cites W2014934394 @default.
• W2789873517 cites W2019607817 @default.
• W2789873517 cites W2038056960 @default.
• W2789873517 cites W2038306303 @default.
• W2789873517 cites W2041710964 @default.
• W2789873517 cites W2043911652 @default.
• W2789873517 cites W2052248211 @default.
• W2789873517 cites W2053419196 @default.
• W2789873517 cites W2069421644 @default.
• W2789873517 cites W2075131732 @default.
• W2789873517 cites W2083222139 @default.
• W2789873517 cites W2100945326 @default.
• W2789873517 cites W2106713309 @default.
• W2789873517 cites W2106729876 @default.
• W2789873517 cites W2107763333 @default.
• W2789873517 cites W2108701193 @default.
• W2789873517 cites W2111005353 @default.
• W2789873517 cites W2111842868 @default.
• W2789873517 cites W2118682535 @default.
• W2789873517 cites W2119335520 @default.
• W2789873517 cites W2120107140 @default.
• W2789873517 cites W2120795894 @default.
• W2789873517 cites W2122956665 @default.
• W2789873517 cites W2123706118 @default.
• W2789873517 cites W2124371732 @default.
• W2789873517 cites W2125519805 @default.
• W2789873517 cites W2130921495 @default.
• W2789873517 cites W2131171455 @default.
• W2789873517 cites W2136146667 @default.
• W2789873517 cites W2140587309 @default.
• W2789873517 cites W2150515509 @default.
• W2789873517 cites W2158011521 @default.
• W2789873517 cites W2173235643 @default.
• W2789873517 cites W2290466312 @default.
• W2789873517 cites W2309779470 @default.
• W2789873517 cites W2334975024 @default.
• W2789873517 cites W2341389059 @default.
• W2789873517 cites W2415972817 @default.
• W2789873517 cites W2477757565 @default.
• W2789873517 cites W2498858311 @default.
• W2789873517 cites W2791083814 @default.
• W2789873517 cites W2921021975 @default.
• W2789873517 cites W4236481024 @default.
• W2789873517 doi "https://doi.org/10.1158/1535-7163.mct-17-0552" @default.
• W2789873517 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5935559" @default.
• W2789873517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29444985" @default.
• W2789873517 hasPublicationYear "2018" @default.
• W2789873517 type Work @default.
• W2789873517 sameAs 2789873517 @default.
• W2789873517 citedByCount "9" @default.
• W2789873517 countsByYear W27898735172018 @default.
• W2789873517 countsByYear W27898735172019 @default.
• W2789873517 countsByYear W27898735172020 @default.
• W2789873517 countsByYear W27898735172021 @default.
• W2789873517 countsByYear W27898735172022 @default.
• W2789873517 countsByYear W27898735172023 @default.
• W2789873517 crossrefType "journal-article" @default.
• W2789873517 hasAuthorship W2789873517A5027165899 @default.
• W2789873517 hasAuthorship W2789873517A5034690406 @default.
• W2789873517 hasAuthorship W2789873517A5036643896 @default.
• W2789873517 hasAuthorship W2789873517A5041200743 @default.
• W2789873517 hasAuthorship W2789873517A5047485406 @default.
• W2789873517 hasAuthorship W2789873517A5057382599 @default.
• W2789873517 hasAuthorship W2789873517A5072996291 @default.
• W2789873517 hasAuthorship W2789873517A5078802338 @default.
• W2789873517 hasAuthorship W2789873517A5080778766 @default.
• W2789873517 hasAuthorship W2789873517A5083899578 @default.
• W2789873517 hasAuthorship W2789873517A5089485306 @default.
• W2789873517 hasAuthorship W2789873517A5090468019 @default.
• W2789873517 hasBestOaLocation W27898735171 @default.
• W2789873517 hasConcept C111113717 @default.

• next